Assessment of Disease‐Related Therapeutic Protein Drug‐Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis

The efficacy and safety of etrolizumab, a humanized IgG1 mAb, were evaluated in patients with ulcerative colitis (UC) in a phase 2 study (EUCALYPTUS). The current study assessed the risk of therapeutic protein drug‐drug interaction (TP‐DDI) of etrolizumab on CYP3A activity in patients with UC. Liter...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiaohui, Kenny, Jane R., Dickmann, Leslie, Maciuca, Romeo, Looney, Caroline, Tang, Meina T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066705/
https://www.ncbi.nlm.nih.gov/pubmed/26412221
http://dx.doi.org/10.1002/jcph.649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066705/
https://www.ncbi.nlm.nih.gov/pubmed/26412221
http://dx.doi.org/10.1002/jcph.649

Ejemplares similares